非霍奇金淋巴瘤抗血管新生治疗的部分机制研究  

Mechanism study of anti-angiogenic therapy in patients with non-Hodgkin lymphoma

作　　者：侯芸华[1] 宋振岚[2] 张永利[1] 刘璟瑶[1] 

机构地区：[1]大连大学附属中山医院血液科,辽宁大连116001 [2]大连医科大学附属二院血液科,辽宁大连116023

出　　处：《临床荟萃》2006年第2期92-95,F0003,共5页Clinical Focus

摘　　要：目的观察沙立度胺(反应停)辅助治疗非霍奇金淋巴瘤(NHL)的临床效果,并测定治疗前后淋巴瘤组织微血管密度(MVD)及血管内皮细胞生长因子(VEGF)、核因子-κB(NF-κB)活性的变化。方法采用免疫组化方法测定实验组17例及对照组14例NHL患者淋巴瘤组织中的VEGF、NF-κB、MVD表达。结果两组病例的有效率[完全缓解(CR)+部分缓解(PR)]分别为70.6%和64.3%,差异无统计学意义(P>0.05)。但CR患者随访6个月以后,实验组1例复发,对照组3例复发;治疗后MVD、VEGF与对照组相比差异有统计学意义,MVD(42.3±19.2)%vs(57.8±19.8)%,VEGF(21.3±5.4)%vs(31.7±5.8)%(P<0.05,P<0.01),NF-κB与对照组相比差异无统计学意义(P>0.05)。结论反应停联合化疗可以维持NHL患者的持续缓解状态,减少复发;其通过降低NHL患者淋巴瘤组织中VEGF的表达,从而减少其MVD而抑制血管新生来达到此作用的。Objective To observe the effect of thalidomide on the patients with non-Hodgkin lymphoma（NHL） and examine the expression of mierovessel density （MVD）, vascular endothelial growth factor （VEGF） and nuclear faetor-κB （NF-κappaB） before and after the treatment. Methods There are 17 cases in combination group, while 14 cases in control one. The expression of MVD, VEGF and NF-κB in tissue samples were examined with immunohistological stain respectively before and 6-8 weeks after the treatment. Results The efficacy rate was 70.6% and 64.3% in the two groups respectively with no statistical difference（ P 〉0.05）. The relapsing rate 6 months after treatment was lower in the combination group. After treatment MVD and VEGF levels were much lower in combination group than those in control group, with significant statistical difference MVD（42.3±19.2） % vs （57.8±19.8）%, VEGF（21.3±5.4）% vs （31.7±5.8） % （ P 〈0.05, P〈0.01）. There was no significant statistical difference in NF-κB between two groups（ P〉0.05, P〈0.01）. Conclusion As an inhibitor of angiogenesis,thalidomide can decrease relapse and maintain recovery rate of NHL patients. The main mechanism is to reduce MVD by inhibiting VEGF production.

关 键 词：淋巴瘤 非霍奇金氏 血管 内皮生长因子类 核蛋白质类 

分 类 号：R733.41[医药卫生—肿瘤]